NASDAQ:OPHT - IVERIC bio Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$5.84
▲ +0.06 (1.04%)
Get New IVERIC bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OPHT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OPHT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for IVERIC bio in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $5.84.
N/A
The current consensus among 0 contributing investment analysts is to n/a stock in IVERIC bio. This rating has held steady since July 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/2/2018Chardan CapitalReiterated RatingHold$4.00Low
i
6/13/2018Chardan CapitalReiterated RatingHold$4.00Low
i
3/19/2018JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightLow
i
9/21/2017Stifel NicolausReiterated RatingHold$4.00Low
i
12/13/2016GabelliDowngradeBuy ➝ HoldN/A
i
Rating by K. Kedra at Gabelli
12/13/2016Morgan StanleyDowngradeOverweight ➝ Equal WeightN/A
i
12/12/2016The Goldman Sachs GroupUpgradeSell ➝ NeutralN/A
i
12/12/2016SVB LeerinkDowngradeOutperform ➝ Market PerformN/A
i
Rating by J. Schwartz at SVB Leerink LLC
12/12/2016Stifel NicolausDowngradeBuy ➝ HoldN/A
i
12/12/2016BTIG ResearchDowngradeBuy ➝ NeutralN/A
i
Rating by ling wang at BTIG Research
12/12/2016CowenDowngradeOutperform ➝ Market PerformN/A
i
Rating by Tyler Van Buren at Cowen Inc
12/12/2016CitigroupDowngradeBuy ➝ NeutralN/A
i
Rating by Yigal Nochomovitz at Citigroup Inc.
12/12/2016BarclaysDowngradeOverweight ➝ Equal WeightN/A
i
12/12/2016JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$11.00N/A
i
Rating by anupam rama at JPMorgan Chase & Co.
12/12/2016SunTrust BanksDowngradeBuy ➝ HoldN/A
i
12/12/2016Chardan CapitalDowngradeBuy ➝ Neutral$15.00N/A
i
Rating by G. Amusa at Chardan Capital
12/2/2016Stifel NicolausReiterated RatingBuy$75.00N/A
i
11/9/2016BarclaysReiterated RatingBuy$70.00N/A
i
10/31/2016BTIG ResearchReiterated RatingBuy$92.00N/A
i
Rating by ling wang at BTIG Research
10/31/2016Chardan CapitalReiterated RatingBuy$200.00N/A
i
10/30/2016CitigroupSet Price TargetBuy$92.00N/A
i
Rating by Yigal Nochomovitz at Citigroup Inc.
10/3/2016BTIG ResearchReiterated RatingBuy$92.00N/A
i
Rating by ling wang at BTIG Research
10/1/2016CowenSet Price TargetBuy$60.00N/A
i
Rating by Tyler Van Buren at Cowen Inc
9/30/2016SVB LeerinkReiterated RatingPositive$72.00N/A
i
9/20/2016BTIG ResearchReiterated RatingBuy$92.00N/A
i
Rating by ling wang at BTIG Research
9/8/2016JPMorgan Chase & Co.Boost Price TargetOverweight$81.00 ➝ $95.00N/A
i
Rating by Anupam Rama at JPMorgan Chase & Co.
8/19/2016BTIG ResearchReiterated RatingBuy$92.00N/A
i
8/10/2016The Goldman Sachs GroupReiterated RatingSell$45.00N/A
i
8/4/2016CitigroupBoost Price TargetBuy$91.00 ➝ $92.00N/A
i
7/19/2016BarclaysReiterated RatingBuyN/A
i
6/2/2016JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$60.00 ➝ $84.00N/A
i
4/27/2016BarclaysInitiated CoverageOverweight$85.00N/A
i
(Data available from 4/21/2016 forward)
IVERIC bio logo
IVERIC bio, Inc. is a biopharmaceutical company which engages in discovering, developing, and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in New York, NY.
Read More

Today's Range

Now: $5.84
$5.62
$5.85

50 Day Range

MA: $1.30
$1.13
$1.39

52 Week Range

Now: $5.84
$1.02
$4.50

Volume

208,725 shs

Average Volume

159,109 shs

Market Capitalization

$241.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49

Frequently Asked Questions

What sell-side analysts currently cover shares of IVERIC bio?

The following Wall Street sell-side analysts have issued reports on IVERIC bio in the last twelve months:
View the latest analyst ratings for OPHT.

What is the current price target for IVERIC bio?

0 Wall Street analysts have set twelve-month price targets for IVERIC bio in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for IVERIC bio in the next year.
View the latest price targets for OPHT.

What is the current consensus analyst rating for IVERIC bio?

IVERIC bio currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for OPHT.

What other companies compete with IVERIC bio?

How do I contact IVERIC bio's investor relations team?

IVERIC bio's physical mailing address is ONE PENN PLAZA 19TH FLOOR, NEW YORK NY, 10119. The biopharmaceutical company's listed phone number is (212) 845-8200 and its investor relations email address is [email protected] The official website for IVERIC bio is www.ophthotech.com.